Compare iShares MSCI Taiwan ETF (EWT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI Taiwan ETF trades at $100.32, while State Street SPDR S&P Biotech ETF trades at $152. Which is the better fit depends on your goals.
| EWT | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $111.53 | $164.28 |
52-Week Low | $58.05 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Taiwan ETF (EWT) trades at $100.08, down 1.77% on the day, consolidating after a significant rally that saw the fund more than double over the past year. Technical indicators show a neutral overall signal with mixed moving average and oscillator readings, while the fund remains strategically positioned at the center of the global AI infrastructure surge through its heavy exposure to Taiwan's semiconductor sector, led by TSMC.
The outlook for EWT is balanced between strong fundamental tailwinds from AI-driven semiconductor demand and significant geopolitical risks related to Taiwan-China tensions. While the fund offers concentrated exposure to a critical technology supply chain, stretched valuations and potential currency headwinds create near-term uncertainty for investors.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
